Researchers analyzed data from over 5,000 adults with type 2 diabetes to see how different SGLT2 inhibitors affect the body. The study looked at several specific medications, including empagliflozin, ipragliflozin, canagliflozin, dapagliflozin, and tofogliflozin. They compared these drugs against placebos or other common treatments over a period of at least 12 weeks.
The results showed that SGLT2 inhibitors consistently reduced fat mass, body weight, and body mass index. These medications also helped lower body fat percentage and waist circumference. While some specific medications like empagliflozin and ipragliflozin were linked to modest reductions in lean mass, the study found no significant reduction in actual skeletal muscle mass across any of the SGLT2 inhibitors.
You should keep in mind that this was a complex analysis of several different studies. Because data on muscle strength and physical performance were rarely reported, it is currently unclear if these medications affect the risk of muscle loss over time. Talk to your doctor to understand how these findings apply to your specific treatment plan.
